ArticleLeukemia2012
Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation.
Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Metabolic Function and Therapeutic Potential of CD147 for Hematological Malignancies: An Overview.International journal of molecular sciences · 2024Review
- Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients-A Proof of Concept.International journal of molecular sciences · 2022Article
- Article
- CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target.The Science of the total environment · 2022Review
- MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.Blood advances · 2022Article
- Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma.Current issues in molecular biology · 2022Article
- BSG (CD147) Serum Level and Genetic Variants Are Associated with Overall Survival in Acute Myeloid Leukaemia.Journal of clinical medicine · 2022Article
- CD147-Cyclophilin a Interactions Promote Proliferation and Survival of Cutaneous T-Cell Lymphoma.International journal of molecular sciences · 2021Article
- HIFZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Long-chain polyunsaturated omega-3 fatty acids reduce multiple myeloma exosome-mediated suppression of NK cell cytotoxicity.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Article
- Mindin serves as a tumour suppressor gene during colon cancer progression through MAPK/ERK signalling pathway in mice.Journal of cellular and molecular medicine · 2020Article
- Article
- OWL-NETS: Transforming OWL Representations for Improved Network Inference.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2018Article
- Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.Oncotarget · 2016Article
- Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.Nature medicine · 2016Article
- Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma.Leukemia · 2016Article
- TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin.Oncotarget · 2016Article
- How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity.Bioscience reports · 2015Review
- Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Multiple myeloma (MM) is preceded by the asymptomatic pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS). Although MGUS patients may remain stable for years, they are at increased risk of progressing to MM. A better understanding of the relevant molecular changes underlying the transition from an asymptomatic to symptomatic disease state is urgently needed. Our studies show for the first time that the CD147 molecule (extracellular matrix metalloproteinase inducer) may be having an important biological role in MM. We first demonstrate that CD147 is overexpressed in MM plasma cells (PCs) vs normal and pre-malignant PCs. Next, functional studies revealed that the natural CD147 ligand, cyclophilin B, stimulates MM cell growth. Moreover, when MM patient PCs displaying bimodal CD147 expression were separated into CD147(bright) and CD147(dim) populations and analyzed for proliferation potential, we discovered that CD147(bright) PCs displayed significantly higher levels of cell proliferation than did CD147(dim) PCs. Lastly, CD147-silencing significantly attenuated MM cell proliferation. Taken together, these data suggest that the CD147 molecule has a key role in MM cell proliferation and may serve as an attractive target for reducing the proliferative compartment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.